相关实验视频

Updated: Jan 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

评估三重疗法在转移性割敏感前列腺癌中的协同效应与添加效应:模型分析

Shinro Hata¹, Shuntaro Suzuki¹, Hiroyuki Fujinami¹

¹Department of Urology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita 879-5593, Japan.

Japanese journal of clinical oncology

|December 30, 2025

概括

阿拉森斯试验显示,三重疗法显著改善了转移性割敏感前列腺癌 (mCSPC) 的存活率. 这种组合疗法提供了比添加剂更大的益处,支持其使用.

科学领域:

在瘤学瘤学.
临床药理学临床药理学
生物统计学生物统计学

背景情况:

转移性割敏感前列腺癌 (mCSPC) 需要有效的治疗策略.
在ARASENS试验中,mCSPC.的三重疗法确立了整体生存 (OS) 益处.
这种好处的性质 (协同效应与添加剂) 仍需要阐明.

研究的目的:

在mCSPC中数学建模并评估三重疗程的益处.
要确定观察到的操作系统好处是协同效应还是仅仅是附加效应.
提供支持mCSPC前期组合治疗的证据.

主要方法:

利用独立药物作用的数学模型.
员工公布了来自ARASENS和ARANOTE试验的数据.
使用重建的个人患者数据和Cox模型,将观察到的OS与预测的OS曲线进行比较.

主要成果:

观察到的三重剂疗法的生存效应在统计学上优于预测的附加效应 (HR 0.82,P=.047),表明临床益处大约为18%.
对随后的抗癌治疗时间的分析显示,更明显的大于附加效益 (HR0.57,P<.001),减轻了以后治疗的混.
三重疗法证明了早期的治疗优势,超过了附加期望.

结论:

在mCSPC的三重疗法提供了一个协同的,而不是纯粹的添加,生存益处.
这些发现支持mCSPC的前期组合策略的临床实用性.
早期的治疗优势表明改善了疾病控制和患者的治疗结果.

关键词:

达洛胺胺的使用方法多塞塔克塞尔 (Docetaxel) 是一种药物.药物协同作用药物协同作用独立的毒品行动行动前列腺癌是前列腺癌.

更多相关视频

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

相关概念视频

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...